Drug intelligence / Profile preview

NTX-471

Development stage: Preclinical
Lead developer: Nutcracker Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

NTX-471 is an early-stage preclinical mRNA therapeutic candidate developed by Nutcracker Therapeutics. It is engineered to specifically target CD47 on cancerous cells using unique mRNA-encoded compositions, including bivalent, tetravalent, hexavalent, and octavalent RNA-encoded SIRPa proteins and bispecific SIRPa-antiCCR4 molecules. The drug aims to block the "do not eat me" signal emitted by CD47 on cancer cells, making them vulnerable to immune system attack by macrophages. Notably, NTX-471 has demonstrated similar anti-tumor activity to existing anti-CD47 therapeutics but with reduced anemia side effects due to its higher specificity for tumor cells over red blood cells[1][5][3].

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on NTX-471.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-471.

Explore the full profile